First referral to an integrated onco-palliative care program: a retrospective analysis of its timing.


Journal

BMC palliative care
ISSN: 1472-684X
Titre abrégé: BMC Palliat Care
Pays: England
ID NLM: 101088685

Informations de publication

Date de publication:
12 Mar 2020
Historique:
received: 26 06 2019
accepted: 03 03 2020
entrez: 14 3 2020
pubmed: 14 3 2020
medline: 31 10 2020
Statut: epublish

Résumé

Palliative care (PC) referral is recommended early in the course of advanced cancer. This study aims to describe, in an integrated onco-palliative care program (IOPC), patient's profile when first referred to this program, timing of this referral and its impact on the trajectory of care at end-of-life. The IOPC combined the weekly onco-palliative meeting (OPM) dedicated to patients with incurable cancer, and/or the clinical evaluation by the PC team. Oncologists can refer to the multidisciplinary board of the OPM the patients for whom goals and organization of care need to be discussed. We analyzed all patients first referred at OPM in 2011-2013. We defined the index of precocity (IP), as the ratio of the time from first referral to death by the time from diagnosis of incurability to death, ranging from 0 (late referral) to 1 (early referral). Of the 416 patients included, 57% presented with lung, urothelial cancers, or sarcoma. At first referral to IOPC, 76% were receiving antitumoral treatment, 63% were outpatients, 56% had a performance status ≤2 and 46% had a serum albumin level > 35 g/l. The median [1st-3rd quartile] IP was 0.39 [0.16-0.72], ranging between 0.53 [0.20-0.79] (earliest referral, i.e. close to diagnosis of incurability, for lung cancer) to 0.16 [0.07-0.56] (latest referral, i.e. close to death relatively to length of metastatic disease, for prostate cancer). Among 367 decedents, 42 (13%) received antitumoral treatment within 14 days before death, and 157 (43%) died in PC units. The IOPC is an effective organization to enable early integration of PC and decrease aggressiveness of care near the end-of life. The IP is a useful tool to model the timing of referral to IOPC, while taking into account each cancer types and therapeutic advances.

Sections du résumé

BACKGROUND BACKGROUND
Palliative care (PC) referral is recommended early in the course of advanced cancer. This study aims to describe, in an integrated onco-palliative care program (IOPC), patient's profile when first referred to this program, timing of this referral and its impact on the trajectory of care at end-of-life.
METHODS METHODS
The IOPC combined the weekly onco-palliative meeting (OPM) dedicated to patients with incurable cancer, and/or the clinical evaluation by the PC team. Oncologists can refer to the multidisciplinary board of the OPM the patients for whom goals and organization of care need to be discussed. We analyzed all patients first referred at OPM in 2011-2013. We defined the index of precocity (IP), as the ratio of the time from first referral to death by the time from diagnosis of incurability to death, ranging from 0 (late referral) to 1 (early referral).
RESULTS RESULTS
Of the 416 patients included, 57% presented with lung, urothelial cancers, or sarcoma. At first referral to IOPC, 76% were receiving antitumoral treatment, 63% were outpatients, 56% had a performance status ≤2 and 46% had a serum albumin level > 35 g/l. The median [1st-3rd quartile] IP was 0.39 [0.16-0.72], ranging between 0.53 [0.20-0.79] (earliest referral, i.e. close to diagnosis of incurability, for lung cancer) to 0.16 [0.07-0.56] (latest referral, i.e. close to death relatively to length of metastatic disease, for prostate cancer). Among 367 decedents, 42 (13%) received antitumoral treatment within 14 days before death, and 157 (43%) died in PC units.
CONCLUSIONS CONCLUSIONS
The IOPC is an effective organization to enable early integration of PC and decrease aggressiveness of care near the end-of life. The IP is a useful tool to model the timing of referral to IOPC, while taking into account each cancer types and therapeutic advances.

Identifiants

pubmed: 32164672
doi: 10.1186/s12904-020-0539-x
pii: 10.1186/s12904-020-0539-x
pmc: PMC7069048
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

31

Références

J Pain Symptom Manage. 2011 Apr;41(4):692-9
pubmed: 21232909
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Ann Palliat Med. 2015 Jul;4(3):89-98
pubmed: 26231806
J Clin Oncol. 2015 May 1;33(13):1438-45
pubmed: 25800768
Lancet Oncol. 2016 Dec;17(12):e552-e559
pubmed: 27924753
Lancet. 2018 Apr 7;391(10128):1391-1454
pubmed: 29032993
Oncologist. 2015 Jan;20(1):56-61
pubmed: 25361623
J Clin Oncol. 2016 Mar 20;34(9):987-1011
pubmed: 26846975
J Clin Oncol. 2012 Mar 10;30(8):880-7
pubmed: 22312101
Oncologist. 2015 Jan;20(1):77-83
pubmed: 25480826
Presse Med. 2015 Jan;44(1):e1-e11
pubmed: 25499252
CA Cancer J Clin. 2018 Sep;68(5):356-376
pubmed: 30277572
Respirology. 2016 Jul;21(5):821-33
pubmed: 27101251
Lancet Oncol. 2018 Nov;19(11):e588-e653
pubmed: 30344075
Ann Pathol. 2016 Jan;36(1):63-72
pubmed: 26775573
J Clin Oncol. 2017 Mar 10;35(8):834-841
pubmed: 28029308
J Clin Oncol. 2017 Jan;35(1):96-112
pubmed: 28034065
J Clin Oncol. 2012 Aug 1;30(22):2715-7
pubmed: 22753911
Int J Qual Health Care. 2005 Dec;17(6):505-9
pubmed: 15985505
JAMA. 2010 Mar 17;303(11):1054-61
pubmed: 20233823
BMJ Support Palliat Care. 2012 Sep;2(3):239-47
pubmed: 24654196
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Lancet. 2014 May 17;383(9930):1721-30
pubmed: 24559581
Eur J Cancer. 2016 Dec;69:110-118
pubmed: 27821313
J Clin Oncol. 2005 Apr 20;23(12):2637-44
pubmed: 15728219
Support Care Cancer. 2011 Jul;19(7):1037-43
pubmed: 21432009
J Clin Oncol. 2007 Jun 10;25(17):2377-82
pubmed: 17557950
BMC Palliat Care. 2017 May 30;16(1):36
pubmed: 28558731
Support Care Cancer. 2008 Mar;16(3):217-22
pubmed: 17318594
J Palliat Med. 2005 Oct;8(5):1025-32
pubmed: 16238515
Cochrane Database Syst Rev. 2017 Jun 12;6:CD011129
pubmed: 28603881
JAMA. 2008 Apr 9;299(14):1698-709
pubmed: 18398082
JAMA Oncol. 2017 Nov 1;3(11):1459-1460
pubmed: 28520825
Oncologist. 2015 Sep;20(9):e26
pubmed: 26253556

Auteurs

Claire Barth (C)

Unité Mobile de Soins Palliatifs, Hôpital Cochin, AP-HP Centre, Paris, France.

Isabelle Colombet (I)

Unité Mobile de Soins Palliatifs, Hôpital Cochin, AP-HP Centre, Paris, France. isabelle.colombet@aphp.fr.
Université de Paris, Public Health, Paris, France. isabelle.colombet@aphp.fr.

Vincent Montheil (V)

Unité Mobile de Soins Palliatifs, Hôpital Cochin, AP-HP Centre, Paris, France.

Olivier Huillard (O)

Oncologie médicale, Hôpital Cochin, AP-HP Centre, Paris, France.

Pascaline Boudou-Rouquette (P)

Oncologie médicale, Hôpital Cochin, AP-HP Centre, Paris, France.

Camille Tlemsani (C)

Oncologie médicale, Hôpital Cochin, AP-HP Centre, Paris, France.

Jérôme Alexandre (J)

Université de Paris, Public Health, Paris, France.
Oncologie médicale, Hôpital Cochin, AP-HP Centre, Paris, France.

François Goldwasser (F)

Université de Paris, Public Health, Paris, France.
Oncologie médicale, Hôpital Cochin, AP-HP Centre, Paris, France.

Pascale Vinant (P)

Unité Mobile de Soins Palliatifs, Hôpital Cochin, AP-HP Centre, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH